Navigation Links
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Date:5/21/2008

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the initiation of the REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) Phase 2 clinical trial of voreloxin (also known as SNS-595), the company's lead anti-cancer therapeutic. The REVEAL-1 trial is being conducted in previously untreated elderly patients with acute myeloid leukemia (AML) who are unlikely to benefit from standard induction therapy. The first patient was enrolled and treated at the Indiana University Melvin and Bren Simon Cancer Center under the care of Larry D. Cripe, M.D., Associate Professor, Department of Medicine, Division of Hematology/Oncology at the Indiana University School of Medicine.

The primary objective of the REVEAL-1 trial is to evaluate voreloxin's anti-leukemic activity as a single agent, measured as either complete remission (CR) or complete remission without full platelet recovery (CRp). The study will also measure the duration of these responses. In order to qualify for the trial, patients must be at least age 60 with previously untreated AML and satisfy at least one of the following factors: poor performance status (PS 2); intermediate or unfavorable cytogenetics; prior antecedent hematologic disorder; or age greater than or equal to 70 years. Patients enrolled in the trial will receive three weekly doses of 72 mg/m2 of voreloxin in a treatment cycle. Approximately 55 patients will be enrolled in the open-label, multi-center REVEAL-1 trial.

"We are pleased to move our voreloxin program forward in AML with this Phase 2 trial. Based on the clinical activity and tolerability profiles observed in our Phase 1 trial of voreloxin in relapsed/refractory AML patients
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
3. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
4. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... 2014   Mast Therapeutics, Inc. (NYSE ... that Santosh Vetticaden, Chief Medical Officer and Senior ... personal reasons, in mid-September.  Edwin L. Parsley ... Pharmaceuticals, which Mast acquired earlier this year, will ... interim Chief Medical Officer.  Dr. Parsley previously was ...
(Date:8/29/2014)... 2014 Research and Markets has ... Industry Report, 2014-2017" report to their offering. ... proportion of reimbursement for medical expenses, the Chinese orthopedic ... scale presenting a CAGR of 19.2% during 2009-2013. Trauma ... segments of orthopedic instruments in China ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Asante Solutions, Inc. (Asante), a medical device company focused ... mark for its Pearl Insulin Pump, the only insulin ... mark is a European proof of conformity that certifies ... Asante has begun discussions with potential distribution partners in ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... Phase I safety trial of Neuralstem,s human spinal cord ... Lou Gehrig,s disease), and unpaid Neuralstem consultant, presented interim ... reported yesterday at the American Academy of Neurology (AAN ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Bringing ... Profit By Search announces the Labor Day discount ... clients will surely get the complete services related to ... SEO professionals, Content Writers, and others do have a ... perfection that reflects in their work and since the ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk ... from Wetumpka, Ala. "In order to help her be able ... came up with a way for her to use her ... the patent-pending Deezers to allow crutches to be used on ... walkers, or canes at the beach. The device reduces the ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
Breaking Medicine News(10 mins):Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... 31 Previous studies have shown that hepatitis C ... African Americans than in whites. However, researchers demonstrate in ... meeting of the American Association for the Study of ... in that recurrent HCV in the transplanted liver progresses ...
... five times more lethal than other strains and has shown ... used to treat MRSA, according to a Henry Ford Hospital ... patients infected with the strain died within 30 days compared ... The average 30-day mortality rate for MRSA bloodstream ...
... with low body fat are at increased risk of ... body fat percentage, according to research being presented at ... Scientific Exposition in San Diego. "Our study indicates ... comments Kamyar Kalantar-Zadeh, PhD (LABioMed at Harbor-UCLA). "The results ...
... World AIDS Day 2008 Campaign, AHF/Cambodia CARES and Cambodian Partners ... PHNOM PENH, Cambodia, Oct. 31 As part of an ... in observance of the Testing Millions ... inaugural testing effort during the annual Water Festival, which marks ...
... Ford Hospital study found that hepatitis B does not increase the ... contributing factor. The results contradict a previous study in ... B infection. Hepatitis B is an inflammation of the liver caused ... the American Association for the Study of Liver Diseases, Annual Meeting ...
... the most seriously ill, experts say , SATURDAY, Oct. 31 ... appears to double the risk of stroke in patients with ... life, a new study finds. , Darbepoetin alfa, marketed ... often prescribed for diabetic patients with chronic kidney disease and ...
Cached Medicine News:Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:For dialysis patients, skinny is dangerous 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: